Offerings / Cellular products / PRP
Platelet-Rich Plasma (PRP)
Platelet-Rich Plasma:
Platelet-Rich Plasma (PRP) refers to plasma with a higher concentration of platelets compared to whole blood, which releases a wide range of biologically active molecules. These molecules include **Platelet-Derived Growth Factor (PDGF)**, **Transforming Growth Factor (TGF)-β**, and **Vascular Endothelial Growth Factor (VEGF)**. In cases of tissue damage, PRP stimulates tissue regeneration because the growth factors (GFs) and glycoproteins (adhesion factors) present in platelet granules and plasma enhance cell division, growth, and differentiation. These characteristics have led PRP to be considered a powerful tool in regenerative medicine and in various medical fields, including tissue repair and wound treatment.
 
History:
In the 1970s, the concept of Platelet-Rich Plasma (PRP) first emerged in hematology. Platelet-rich plasma was primarily used for blood transfusions for patients suffering from low platelet counts in their blood. Subsequently, in the 1980s and 1990s, Platelet-Rich Plasma was utilized as a treatment for a wide range of medical conditions. Today, PRP is used in the treatment of orthopedic disorders such as **osteoarthritis**, **ligament and tendon strains**, **tendon tears**, **rotator cuff tears**, and **rheumatoid arthritis**. It's also applied in **nerve damage repair**, **skin and diabetic wound healing**, **infertility**, **skin rejuvenation**, **hair loss**, and in **dermatology and aesthetics**.
 
Allogeneic and Autologous PRP:
PRP can be prepared from various sources, such as an individual's own peripheral blood, another individual, or umbilical cord blood. When it's taken from the patient's own blood, it's called **autologous PRP**, and the latter two cases are referred to as **allogeneic PRP**.
 

Allogeneic and Autologous PRP:

 

 PRP can be prepared from various sources such as an individual's own peripheral blood, another individual's blood, or umbilical cord blood. The first case, where PRP is taken from the patient's own blood, is called **autologous PRP**, and the latter two cases are referred to as **allogeneic PRP**.

 


Advantage of Allogeneic PRP over Autologous:
 

The concentration of certain biologically active components in PRP derived from umbilical cord blood is higher compared to peripheral blood. With age, the body's ability to regenerate and repair tissue decreases, which can reduce the effectiveness of autologous PRP treatment in older individuals. Also, the quantity and type of bioactive substances released by PRP differ in older individuals compared to younger ones. This difference can also lead to a decrease in PRP effectiveness in older age. Furthermore, its clinical use might be limited in some patients, such as the elderly, physically disabled, infants, and children, where repeated blood collection is difficult or clinically inappropriate. Diseases such as cancer, chronic hypertension, acute coronary artery disease, renal vascular dysfunction, gastrointestinal bleeding, and blood disorders like anemia, thrombocytopenia, leukemia, and lymphoma cachexia also limit the possibility of blood collection and preparation of autologous PRP. The high content of tissue-regenerating factors in umbilical cord blood platelets makes umbilical cord blood an ideal source for allogeneic PRP production. Therefore, allogeneic PRP can provide a more consistent and reliable therapeutic effect. 

 

 

Clinical Trials:
 

Umbilical cord blood is a rich source of stem cells with the lowest immunogenicity, and its use in PRP preparation is considered an important research objective for future studies. In this regard, the research and development group of this company was prompted to produce PRP derived from umbilical cord blood. The company's research and development group, in one of their clinical trials, investigated the safety and efficacy of intra-articular transplantation of three sequential doses of allogeneic umbilical cord blood-derived platelet-rich plasma in patients with knee osteoarthritis. This study is being conducted in Phase 1 on 6 patients and in Phase 2 on 24 patients. This group is also conducting another study on the feasibility of producing and characterizing products obtained from allogeneic umbilical cord blood-derived platelet-rich plasma.



Outlook for the Use of Platelet-Rich Plasma


Today, Platelet-Rich Plasma (PRP) has been proven capable of treating a wide range of diseases, and extensive research is underway on the use of umbilical cord blood-derived platelet-rich plasma. This company's research and development group is continuously developing and optimizing these products. By continuing research and participating in clinical trials, we hope to expand the scope of use for these products and contribute to improving patient health at both national and international levels.

If you would like to learn more about our products and research, please contact us or visit the research section of our website. With your support, we are taking an effective step towards advancing science and new treatments.